{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-171647","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.685588+00:00","generated_at":"2026-05-17T21:46:51.998392+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"confidence":"high","headline":"Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair","bullets":["Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.","Dr. Waksal eligible for severance per employment agreement upon signing separation and release.","Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.","Jim Tobin remains as Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-171647","json":"https://secwatch.observer/filing/0001193125-25-171647.json","markdown":"https://secwatch.observer/filing/0001193125-25-171647.md","text":"https://secwatch.observer/filing/0001193125-25-171647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/0001193125-25-171647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/d949358d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:46:51.998392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}